Binx Health Receives CE Mark for Rapid Testing for Chlamydia and Gonorrhea in the Mass Market | 01:05:19



[ad_1]

Multiple test panel for binx io treatment platform ® for radical reduction of treatment time and better care

BOSTONMay 1, 2019 / PRNewswire / – binx health ™, a leader in healthcare worldwide, today announced that its proprietary chlamydia and gonorrhea (CT / NG) test has received European CE certification. The new multiple test uses the binx platform ioto provide lab quality results in about 30 minutes. This is a new model of testing and treatment in the treatment of two of the most common sexually transmitted diseases these days.

Every day, there are more than one million sexually transmitted infections worldwide. Chlamydia and gonorrhea are among the most common.1 Data recently published by the European Center for Disease Prevention and Control (ECDC) show a large increase in cases of gonorrhea in EU / EEA countries by 17% between 2016 and 2017. Some countries reported increases of more than 40% in the annual comparison.2 Likewise, infection rates in the USA since 2013 increased a staggering 67%. In the age group of 20 to 24 years, the numbers are still higher.3

Currently, most tests are being sent to central CT / NG laboratories. This means that from the first consultation until the treatment can take up to seven days, in which patients could pass the infection. Up to 40% of patients with positive results also do not return for treatment.4 Binx has positioned itself to radically change these conditions. Patients and consumers can leave pharmacies, doctors' offices, clinics, emergency departments and other health facilities after a single treatment visit. (The binx treatment platform is in fact in the USA not yet available, but has recently completed its multi-site clinical trial for approval by the US Food and Drug Administration under Section 510 (k).) The binx platform io is easy to use and also allows untrained persons to perform a test with the same accuracy as the tests in the central laboratory. This makes it ideal for use in a variety of drug and consumer acceptable environments.

"Achieving a diagnosis for two of the most common sexually transmitted diseases in 30 minutes is a major breakthrough in public health," said Dr. Howard Heller, MPH.. Chief Medical Officer of binx health. "Rapid results mean rapid and appropriate treatment, this new panel paves the way for testing and treatment not only on the same day, but on the same visit, which breaks down a major obstacle to treatment and cure."

"Modern health needs tools that address the needs of consumers where they live, work and shop," he said. Jeffrey Luber, CEO of binx health. "Doing this effectively means delivering fast, accurate and cost-effective solutions at multiple locations, as well as online medical indexing tests that will free consumers of the concern and recover where they are most comfortable for them. high quality of all forms for general health, through scientific precision, standardized testing and customer focus. The starting point are young people and sexually transmitted diseases. "

About health binx
binx health ™
is a pioneer in caring for patients wherever they live, work and shop. We do this by: (1) Legally protected high-speed desktop PCR instruments for pharmacies, emergency care, doctors' offices, clinics, and all other locations where on-site testing and rapid results with accuracy comparable to lab tests are critical; Mobile home testing solutions that puts you in the hands of consumers to get rid of worries and improve. We begin with sexually transmitted diseases and seek to reverse the trend of increasing infections among young people. It follows more general health care, expanding our practice and domestic offerings. Investors in health binx include financial investors Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB Biotech, RMI Investments and Technology Venture Partners, and strategic investors Consort Medical (whose wholly-owned subsidiary is Bespak's exclusive multi-cartridge manufacturer) and China's Wondfo Biotech.

1 Facts of WHO, 28. Feb 2019
2 ECDC EUROPE
3 Division of STD Prevention, National Center for HIV / AIDS, Viral Hepatitis, STD and Tuberculosis Prevention, Centers for Disease Control and Prevention
4 Dom, Thomas L. et al. Tran's sex: April 1999 – Volume 26 – Issue 4 – P. 232-240

Logo – https://mma.prnewswire.com/media/880236/binx_Logo.jpg

[ad_2]

Source link